Article

Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

This publication includes a summary of data on the treatment of patients with EGFR exon 20 insertions in non–small cell lung cancer (NSCLC) and the rapidly changing landscape of HER2-targeted treatment. Thoracic oncologists, who specialize in the treatment of lung cancer, provide key insights on the current management of uncommon EGFR mutations in NSCLC and the emerging treatment landscape of targeted therapies.

Related Videos
Hossein Borghaei, DO, MS, of Fox Chase Cancer Center
Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists
Sarah B. Goldberg, MD, MPH
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center
Zofia Piotrowska, MD, MHS, of Massachusetts General Hospital
Julie R. Brahmer, MD, of Johns Hopkins Medicine
Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.
Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.
Mary Jo J. Fidler, MD
Related Content
Pasi A. Jänne, MD, PhD
January 30th 2021

Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC